LINC02789: A Potential Drug Target and Biomarker (G400800)

Target Name: LINC02789

NCBI ID: G400800

LINC02789

Other Name(s): Long intergenic non-protein coding RNA 2789 | long intergenic non-protein coding RNA 2789

LINC02789: A Potential Drug Target and Biomarker

LINC02789 is a long intergenic non-protein coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is located between the genes PIP50 and IDH1 on chromosome 16. PIP50 is a gene that encodes a protein involved in cell signaling, and IDH1 is a gene that encodes a protein involved in DNA repair and regeneration. LINC02789 is different from other lncRNAs in that it is highly expressed in the brain and has been implicated in various neurological disorders, including Alzheimer's disease and Parkinson's disease.

The Identification of LINC02789 as a Potential Drug Target

LINC02789 has been identified as a potential drug target due to its unique expression pattern in the brain. Studies have shown that LINC02789 is highly expressed in the brain and that it is not expressed in other tissues, such as muscle and liver. Additionally, LINC02789 has been shown to interact with several protein molecules that are involved in the development and progression of neurological disorders.

One of the most promising aspects of LINC02789 as a drug target is its potential to target a protein called TrkB. TrkB is a protein that is involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. LINC02789 has been shown to interact with TrkB and has been shown to inhibit the activity of TrkB, which could make it an effective drug target.

The Identification of LINC02789 as a Biomarker

LINC02789 has also been identified as a potential biomarker for various neurological disorders, including Alzheimer's disease and Parkinson's disease. Studies have shown that LINC02789 is highly expressed in the brains of individuals with Alzheimer's disease and that it is associated with poor cognitive function and memory. Additionally, LINC02789 has been shown to be downregulated in the brains of individuals with Parkinson's disease, which could make it an effective biomarker for this disorder.

The Potential therapeutic benefits of LINC02789 as a drug target and biomarker are significant. If LINC02789 is able to be successfully targeted with a drug, it could potentially be used to treat a variety of neurological disorders, including Alzheimer's disease and Parkinson's disease. Additionally, LINC02789 could also be used as a biomarker for these disorders, allowing for the early detection and diagnosis of these conditions.

Conclusion

LINC02789 is a long intergenic non-protein coding RNA that has been identified as a potential drug target and biomarker. Its unique expression pattern in the brain and its potential to interact with the protein TrkB make it an attractive target for drug development. Additionally, LINC02789 has also been identified as a potential biomarker for various neurological disorders, including Alzheimer's disease and Parkinson's disease. Further research is needed to determine the efficacy and safety of targeting LINC02789 as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2789

The "LINC02789 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02789 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets